Interview with Jon Himoff - Image Analysis Group (IAG)

When a Phase 3 trial changes imaging vendors mid-study, the problems sponsors hit are rarely the ones they planned for. Not scanner protocols, not endpoint disputes: an outgoing vendor with no reason to hurry, sites juggling incompatible systems, and readers losing time to data entry. Moe Alsumidaie, Chief Editor of Clinical Trial Vanguard, talks to Jon Himoff, Chief Product Officer at Image Analysis Group (IAG), about what purpose-built clinical trial imaging infrastructure actually means once a study goes off script. In this interview: Why sites only need a browser to come onto DYNAMIKA(TM), and why low friction decides the transition timeline Why getting data out of the previous imaging vendor is an incentive problem, not a technical one What it means that IAG designed, built and runs DYNAMIKA(TM) itself on Google Cloud How workflow configuration replaces development work for study-specific setups GxP, 21 CFR Part 11 and SOC 2 compliance, and why building the system yourself lets you be direct about what it will and will not do Streaming trial data as often as every hour for real-time clinical trials Chapters 0:00 Introduction 0:30 Why sponsors underestimate mid-study logistics 3:24 What a sponsor carries forward from one study to the next 7:48 How configurability makes IAG a preferred vendor 9:19 Why purpose-built beats assembled general-purpose tools 11:26 Responding when a study needs something non-standard 13:17 How sponsors notice purpose-built infrastructure 15:48 Why the infrastructure decision comes before the first patient 17:55 Closing Read the full interview on Clinical Trial Vanguard: https://www.clinicaltrialvanguard.com... More from Image Analysis Group (IAG): https://www.ia-grp.com/ Get the weekly briefing: https://www.clinicaltrialvanguard.com... #ClinicalTrials #MedicalImaging #ImagingCRO #ClinicalResearch #Phase3 #ClinicalOperations #DrugDevelopment #ClinicalTrialImaging